FDA (Ghana)

Ghana FDA (Food and Drugs Authority) is the Ghanaian national regulatory authority responsible for regulating food, drugs, cosmetics, medical devices, household chemicals, tobacco + blood/blood products in Ghana. Ghana FDA was established under the Public Health Act 851 of 2012 (Part 7), which consolidated + replaced the Food and Drugs Board (FDB) created under PNDC Law 305B of 1992. The transition from FDB to Ghana FDA in 2012 substantially expanded the agency's mandate + powers + created a Board governance structure substantively similar to the FDA + EMA + MHRA Board models. Ghana FDA's headquarters is in Accra at Cantonments + the agency operates Regional Offices across all 16 Ghanaian regions + Port-of-Entry offices at Tema + Takoradi seaports + Kotoka International Airport + land borders (Aflao with Togo, Elubo with Côte d'Ivoire, Paga with Burkina Faso, Hamile with Burkina Faso).

Ghana FDA's organisational structure includes:

• Chief Executive Officer (CEO) — chief executive appointed by the President of Ghana + accountable to the Minister of Health + the Board of the Authority; serves a 4-year term renewable once.
• Board of the Authority — 9-member board chaired by a Ministerial appointee + including the CEO + representatives of the Ministry of Health + Ministry of Trade + Ministry of Finance + Ghana Standards Authority + Pharmacy Council + Medical & Dental Council + Veterinary Council + civil society.
• Drugs Division — drug registration, generics, biosimilars, vaccines, biologicals, herbal medicines, nutraceuticals.
• Food Industrial Support Services Division — food registration, packaged water, food fortification, food labelling, allergens.
• Medical Devices Division — medical-device + IVD registration + post-market materiovigilance.
• Cosmetics & Household Chemical Substances Division — cosmetics + household chemicals registration.
• Tobacco & Substances of Abuse Division — tobacco product registration + control + substances-of-abuse monitoring.
• Inspectorate Division — GMP / GDP / GCP inspection of Ghanaian + foreign facilities + ports-of-entry.
• Safety Monitoring Division — pharmacovigilance + materiovigilance + post-market surveillance + risk communication.
• Laboratory Services Division — Drug Quality Control Laboratory + Food Microbiology + Food Chemistry + Cosmetics + Medical Device Testing Laboratory; quality-control testing.
• Regulatory Affairs Division — regulations drafting + international engagement + WHO/AMRH/ECOWAS-MRH coordination.
• Communication & Public Education Division — consumer education + risk communication + media relations.

Ghana FDA is distinct from + complementary to: the Pharmacy Council of Ghana (which regulates pharmacy practice + pharmacist registration + pharmacy premises licensing); the Medical & Dental Council (which regulates medical practice); the Ghana Health Service (responsible for primary healthcare delivery + EPI immunisation programmes); the Ministry of Food and Agriculture (which regulates primary agricultural production); + the Ghana Standards Authority (GSA, which sets non-health-related industrial standards + cooperates with FDA on enforcement).

Legal foundations are the Public Health Act 851 of 2012 (Part 7: Food and Drugs Authority), the Ghana FDA Guidelines for Registration of Allopathic Medicinal Products, the Ghana FDA Good Manufacturing Practice Guidelines, the Ghana FDA Medical Devices Guidelines + Ghana FDA Good Clinical Practice Guidelines + a substantial body of Ghana FDA technical guidelines implementing the framework.

Ghana FDA achieved WHO Maturity Level 3 (ML3) for vaccines in December 2020 — making Ghana the first sub-Saharan African NRA to achieve ML3 + positioning Ghana FDA as a regional reference regulator within the AU African Medicines Agency (AMA) framework + the AUDA-NEPAD AMRH framework. Ghana also hosted the first delivery of COVAX vaccines in February 2021 — symbolically + practically anchored by Ghana FDA's ML3 capacity to release imported vaccines. Ghana FDA has applied for PIC/S Membership + is an active participant in WHO PQ CRP, ECOWAS-MRH, AMRH + ICDRA.

Ghanaian pharmaceutical regulation operates under a layered framework of primary legislation + Ghana FDA guidelines:

• Public Health Act 851 of 2012 (Part 7: Food and Drugs Authority) — primary legislation establishing Ghana FDA + its functions, powers + governance; provides for ministerial direction + CEO appointment + Board of the Authority.
• Ghana FDA Guidelines for Registration of Allopathic Medicinal Products — current registration framework for medicines + biologicals + biosimilars + vaccines.
• Ghana FDA Guidelines for Registration of Herbal Medicinal Products — herbal medicines + nutraceuticals framework with traditional-knowledge recognition.
• Ghana FDA Good Manufacturing Practice Guidelines — current Ghanaian GMP guidelines substantively aligned with WHO TRS 986 Annex 2 + ICH Q7 + EU GMP; mandatory for Ghanaian + foreign manufacturers exporting to Ghana.
• Ghana FDA Good Clinical Practice Guidelines — substantively aligned with ICH E6(R2) GCP; mandatory for clinical trials conducted in Ghana.
• Ghana FDA Good Distribution Practice Guidelines — substantively aligned with WHO + EU GDP.
• Ghana FDA Safety Monitoring (Pharmacovigilance) Guidelines — substantively aligned with WHO + EU GVP Modules.
• Ghana FDA Medical Devices Guidelines — risk-based Class A-D framework substantively aligned with GHTF/IMDRF + EU MDR + ISO 13485 with Ghanaian-specific overlay.
• Ghana FDA Cosmetic Products Guidelines — registration + labelling + safety substantiation for cosmetics.
• Ghana FDA Food Registration + Labelling Guidelines — food + packaged water + nutraceutical registration + Ghanaian-language + Ghanaian-specific labelling.
• Ghana FDA Variations Guidelines — Type IA / IB / II variations procedure substantively similar to WHO + EU + ECOWAS-MRH variations framework.
• Ghana FDA Advertising of Medicines Guidelines — pre-approval of medicines + medical-device + food advertising + promotional materials.
• Ghana FDA Mobile Authentication Service — mPedigree-derived scratch-code anti-counterfeit framework for selected high-risk medicines (substantively similar to NAFDAC MAS).
• Ghana FDA Tobacco Control Regulations — graphic health warnings + plain packaging + advertising bans implementing the WHO FCTC.

Ghana FDA medical-device + IVD regulation operates under the Ghana FDA Medical Devices Guidelines with a Class A-D risk-based framework substantively aligned with GHTF/IMDRF + EU MDR. Foreign manufacturers must appoint a Ghanaian Authorised Representative (GAR).

• Risk-based Classification (Class A / B / C / D + IVD Class A-D) — substantively aligned with GHTF/IMDRF + EU MDR/IVDR with Ghanaian-specific overlay.
• Registration Certificate — issued by Ghana FDA Medical Devices Division based on technical-file review + Ghanaian Authorised Representative designation + Ghanaian-language labelling.
• Ghanaian Authorised Representative (GAR) — Ghanaian-resident legal entity required for foreign manufacturers; bears post-market materiovigilance responsibility + Ghanaian regulatory interface.
• ISO 13485:2016 — recognised by Ghana FDA as QMS evidence framework; Ghanaian-specific overlay required including Ghanaian quality records + GAR QMS interface.
• Reliance pathways — Ghana FDA accepts CE Mark + FDA 510(k) + Health Canada + TGA + Swissmedic + MFDS + Japan-approval evidence as supporting evidence under reliance framework; reliance reduces dossier requirements + accelerates review.
• MDSAP — Ghana is not currently an MDSAP Participating Regulator + does not accept MDSAP audit reports as direct QMS evidence; ISO 13485 + Ghanaian-specific overlay required.
• Post-market Materiovigilance — Ghana FDA operates medical-device adverse-event reporting; reporting timelines substantively aligned with IMDRF Adverse Event Reporting Codes.
• Cosmetic Notification — cosmetics under Ghana FDA Cosmetic Products Guidelines require registration + Ghanaian-specific labelling; INCI-aligned ingredient listing + safety substantiation.
• Ghanaian UDI — Ghana FDA has not implemented full UDI equivalent to FDA UDI or EU EUDAMED UDI; Ghanaian-specific labelling + product-identification requirements apply.
• Importation Permit — Ghana FDA Importation Permit required in addition to registration for foreign-manufactured devices entering Ghana.

Ghana FDA achieved WHO Maturity Level 3 (ML3) for vaccines in December 2020 — making Ghana the first sub-Saharan African NRA to achieve ML3 + the second African NRA after Tanzania TMDA + Egypt's NORCB to do so. This is a foundational regulatory milestone for sub-Saharan Africa.

• WHO Global Benchmarking Tool (GBT) — WHO assessment framework for NRA maturity across nine regulatory functions (RS, MA, VL, LT, CT, RI, MC, LR, MA-PMS); Maturity Level 1 through Maturity Level 4 (continuous improvement + advanced reliance).
• Maturity Level 3 (Stable, Well-Functioning + Integrated) — represents WHO's threshold for designating an NRA as a Reference Authority capable of conducting full scientific review + GMP inspection + lot release with international acceptability.
• Ghana FDA ML3 for vaccines (December 2020) — first sub-Saharan African NRA to achieve ML3 for vaccines; achieved through multi-year institutional development with WHO + AUDA-NEPAD + Gates Foundation + Gavi support; positions Ghana FDA as a vaccine NRA reference within the African Medicines Agency framework.
• COVAX symbolic anchor — Ghana hosted the first delivery of COVAX vaccines globally in February 2021 (600,000 doses of AstraZeneca/Oxford vaccine from the Serum Institute of India); Ghana FDA's ML3 capacity was the practical enabler of that landmark release.
• African Medicines Agency (AMA) — AU initiative to create a continental medicines agency (substantively similar to EMA for the EU); AMA Treaty entered into force November 2021; Ghana FDA ML3 status positions Ghana as a leading AMA Member State.
• AUDA-NEPAD AMRH (African Medicines Regulatory Harmonisation) — AU programme advancing regulatory harmonisation across African Regional Economic Communities (RECs); Ghana FDA is a leading AMRH participant + ECOWAS-MRH co-Reference Authority alongside NAFDAC.
• ECOWAS-MRH (ECOWAS Medicines Regulatory Harmonisation) — West African Health Organisation (WAHO)-led programme harmonising medicines regulation across 15 ECOWAS Member States; Ghana FDA + NAFDAC co-lead ECOWAS-MRH Joint Assessment Procedure as the most mature ECOWAS NRAs.
• ML4 ambition — Ghana FDA has indicated intention to pursue WHO Maturity Level 4 (Continuous Improvement + Advanced Reliance) for vaccines + ML3 for medicines as next milestones.
• ML3-driven CRP eligibility — Ghana FDA ML3 for vaccines enables full participation in WHO CRP as both CRP Recipient + CRP Reference Authority for African Region products.

• WHO Maturity Level 3 for Vaccines (December 2020) — first sub-Saharan African NRA to achieve ML3 for vaccines.
• WHO PQ Collaborative Registration Procedure (CRP) — active WHO PQ CRP Recipient + Reference; substantial use of CRP for vaccines + HIV + malaria + tuberculosis medicines.
• AUDA-NEPAD AMRH — leading participant in African Medicines Regulatory Harmonisation programme; co-leads ECOWAS-MRH work-stream alongside NAFDAC + AU AMA Treaty implementation.
• ECOWAS-MRH (West African Health Organisation / WAHO) — Ghana FDA + NAFDAC are the most mature ECOWAS NRAs + co-lead ECOWAS-MRH Joint Assessment Procedure for medicines + vaccines across 15 ECOWAS Member States.
• African Medicines Agency (AMA) — AU continental medicines agency under AMA Treaty (entered into force November 2021); Ghana FDA is a leading AMA Member State.
• WAHO Regional Centre of Regulatory Excellence (RCORE) — University of Ghana hosts the WAHO RCORE for clinical-trial regulation + Ghana FDA provides operational support.
• PIC/S Application — Ghana FDA has applied for PIC/S Membership; Ghana FDA GMP Guidelines + inspectorate practices substantively aligned with PIC/S GMP Guide + Annexes.
• ICDRA Member — active International Conference of Drug Regulatory Authorities participant; hosts ICDRA-related Africa-Region preparatory meetings.
• ICH Observer — Ghana FDA is an ICH Observer; ICH guidelines extensively referenced in Ghanaian regulatory practice.
• Bilateral MoUs — Ghana FDA holds MoUs with FDA + EMA + MHRA + Health Canada + TGA + ANVISA + NMPA + MFDS + NAFDAC + SAHPRA + Egyptian EDA + Kenyan PPB + Tanzanian TMDA + Ugandan NDA + Rwandan FDA.
• Gavi / Global Fund / Gates Foundation cooperation — Ghana FDA works closely with Gavi (vaccine procurement), Global Fund (HIV/TB/malaria procurement) + Gates Foundation (regulatory strengthening).
• COVAX + COVID-19 response — Ghana FDA hosted the first global COVAX vaccine delivery (February 2021) + has provided substantial ML3-driven regulatory leadership across the African Region COVID-19 response.
• IMDRF Affiliate — Ghana FDA is an IMDRF Affiliate Member + draws on IMDRF guidance for medical-device regulation.

• Ghanaian Authorised Representative or local Sponsor not properly designated — application rejected at Ghana FDA intake or post-approval compliance failure.
• Ghanaian-specific labelling deficiencies — English (Ghana's official language) + Ghanaian-Cedi pricing-reference + Ghanaian PIL + storage-condition Ghanaian-climate appropriateness.
• GMP Guidelines gaps — applicants assuming EU GMP / PIC/S GMP compliance is sufficient without addressing Ghana-specific Ghana FDA GMP Guidelines + Ghana FDA-specific clarifications.
• Ghanaian climate-zone stability data missing — Ghanaian Climate Zone IVb (hot + very humid) stability data required for medicines + biologicals; many EU-only + US-only stability packages insufficient.
• WHO PQ CRP eligibility not leveraged — WHO-PQ-approved products eligible for accelerated CRP review at Ghana FDA; missed opportunity for substantial review time + cost reduction.
• ECOWAS-MRH joint assessment not leveraged — ECOWAS-MRH joint assessment + reliance pathway underutilised by applicants targeting multiple West African markets.
• Variations strategy not planned — Type IA / IB / II variations procedure substantively similar to WHO but with Ghana-specific timelines + fee structure.
• Renewal timing missed — 5-year renewal must be filed within prescribed window before expiry; missed deadline triggers de-registration + market withdrawal.
• Importation Permit not obtained — Ghana FDA Importation Permit required in addition to registration for foreign-manufactured medicines + devices entering Ghana.
• Port-of-entry inspection gaps — Ghana FDA Inspectorate inspection at Tema + Takoradi seaports + Kotoka airport + land borders; importer logistics planning must account for inspection clearance time.
• Pharmacovigilance reporting gaps — Ghana FDA Safety Monitoring requirements substantively similar to WHO GVP + EU GVP but with Ghanaian-specific format requirements + Ghanaian-population pharmacovigilance focus.
• Cosmetics + nutraceutical scope misjudged — Ghana FDA broad mandate means cosmetics + nutraceuticals require active Ghana FDA registration that some sponsors mistakenly assume is exempt.
• Advertising pre-approval missed — Ghana FDA advertising regulations require pre-approval of medicines + medical-device + food advertising + promotional materials.
• Tobacco / household-chemical scope not anticipated — Ghana FDA regulates tobacco + household chemicals; sponsors with adjacent product lines must account for these additional Ghana FDA divisional touchpoints.
• Clinical trial GCP gaps — Ghana FDA GCP Guidelines substantively aligned with ICH E6(R2) but with Ghana-specific Ethics Committee + GHS coordination requirements.

V5 Ultimate provides the operational infrastructure Ghanaian + foreign-supplier sites need for Public Health Act 851 of 2012 + Ghana FDA GMP Guidelines + Ghana FDA Drug Registration + Ghana FDA Medical Devices Guidelines + ECOWAS-MRH + WHO PQ CRP readiness.

• Ghana FDA GMP Guidelines control framework — WHO TRS 986 Annex 2 + ICH Q7 + EU GMP-aligned controls (clean rooms, aseptic process, environmental monitoring, computerised systems) with ALCOA+ data-integrity + Ghana-specific clarifications + Ghanaian climate-zone IVb stability monitoring.
• Ghana FDA drug-registration packaging — Ghanaian CTD-aligned dossier structure with Ghana Module 1 specifics + Module 3 stability + Ghanaian PIL + English labelling + Ghanaian Authorised Representative declarations.
• WHO PQ CRP workflow — CRP Recipient packaging with WHO PQ Assessment Report + Ghana FDA-specific overlay + reduced dossier + accelerated 90-day review path.
• ECOWAS-MRH workflow — ECOWAS-MRH joint assessment + reliance pathway packaging for multi-country West African registration including Ghana + Nigeria + Côte d'Ivoire + Senegal + Mali + Burkina Faso.
• AMRH + AMA workflow — AU AMA + AUDA-NEPAD AMRH reliance pathway packaging for continental coverage.
• Ghanaian Authorised Representative workflow — foreign-manufacturer GAR designation + role-management + Ghana-specific post-market surveillance + Ghana FDA interface.
• Ghanaian clinical-trial workflow — Ghana FDA Good Clinical Practice + GHS Ethics Review Committee + Ghana-population pharmacovigilance + Ghana FDA CTA submission + Ghanaian SUSAR reporting.
• Ghana FDA Safety Monitoring pharmacovigilance — E2B(R3) ICSR generation + 15-day SUSAR timeline + PSUR / PBRER packaging + Ghana-specific format + Ghana FDA Safety Monitoring platform integration.
• Medical-device + cosmetic + nutraceutical workflow — Ghana FDA Medical Devices Guidelines + Cosmetic Guidelines + Nutraceutical Guidelines dossier packaging + Class A-D + IVD classification + ISO 13485 + Ghanaian Authorised Representative + post-market materiovigilance.
• Ghana FDA Variations workflow — Type IA / IB / II classification + Ghana FDA procedure + Ghanaian packaging.
• Renewal workflow — 5-year renewal window tracking + Ghana FDA procedure packaging.
• ECOWAS + AU regional bridging — for companies operating across West Africa + Africa, V5 surfaces Ghana FDA + NAFDAC + Ivorian + Senegalese + Malian + Burkinabé + South African SAHPRA + Egyptian EDA + Kenyan PPB + Ugandan NDA + Rwandan FDA harmonised dossier-element reuse alongside national-specific extensions.